BC
VRDN icon

Bridgefront Capital’s Viridian Therapeutics VRDN Stock Holding History

Bridgefront Capital’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-21,366
Closed -$665K – 777
2025
Q4 		$665K Buy
+21,366
New +$586K 0.17% 205
2024
Q3 		– Sell
-15,709
Closed -$204K – 732
2024
Q2 		$204K Buy
+15,709
New +$217K 0.09% 411

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Bridgefront Capital's VRDN Position: Q1 2026 in Review

Bridgefront Capital sold out of Viridian Therapeutics (VRDN) in Q1 2026, closing a stake of 21,366 shares — an estimated $665K sold.

Bridgefront Capital first reported a position in VRDN in Q2 2024 and held it in 2 quarters. The position peaked at $665K in Q4 2025. 225 funds tracked by Wall St. Rank hold VRDN as of Q1 2026.

  • Bridgefront Capital reported no remaining Viridian Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Bridgefront Capital sold 21,366 Viridian Therapeutics shares in Q1 2026, an estimated $665K.
  • Bridgefront Capital first reported a position in Viridian Therapeutics in Q2 2024 and held it in 2 quarters.
  • Bridgefront Capital's Viridian Therapeutics position peaked at $665K in Q4 2025.
  • 225 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q1 2026.

Based on Bridgefront Capital's 13F filing for Q1 2026, filed 15 May 2026.